제이앤티팜

비상장계속사업자

J&T Pharm

최종태, 이창호

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

제이앤티팜

Business Reg. No. 2158679762 · CEO 최종태, 이창호

I.Investment Overview

Target제이앤티팜 (2158679762)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명제이앤티팜
영문명J&T Pharm
대표자최종태, 이창호
사업자등록번호2158679762
법인등록번호1101113364934
설립일2005.12.22

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW502.92021460.62022429.42023436.22024452.12025
영업이익100M KRW43.2202132.6202223.7202321.2202410.72025
순이익100M KRW35.1202126.5202217.7202318.8202411.72025
Item20252024202320222021
자산총계287억원279.3억원284.5억원283.3억원287.4억원
부채총계36.3억원40.3억원64.3억원80.8억원111.5억원
자본총계250.7억원239억원220.2억원202.5억원175.9억원
매출액452.1억원436.2억원429.4억원460.6억원502.9억원
영업이익10.7억원21.2억원23.7억원32.6억원43.2억원
순이익11.7억원18.8억원17.7억원26.5억원35.1억원

VI.Financial Ratios

FY2025 basis

2.37%

영업이익률

2.58%

순이익률

4.06%

ROA

4.65%

ROE

14.5%

부채비율

87.34%

자기자본비율

VII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

제이앤티팜 투심보고서 | Alpha Lenz